Identification of Jun loss promotes resistance to histone deacetylase inhibitor entinostat through Myc signaling in luminal breast cancer
Maki Tanioka(University of North Carolina at Chapel Hill), Charles M. Perou(University of North Carolina at Chapel Hill), David B. Darr(University of North Carolina at Chapel Hill), Kevin R. Mott(University of North Carolina at Chapel Hill), Daniel P. Hollern(University of North Carolina at Chapel Hill), Cheng Fan(University of North Carolina at Chapel Hill)
Cited by 18
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma
|Clinical Cancer Research|2004|2.7k
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer
|Breast Cancer Research|2010|2.1k
The molecular portraits of breast tumors are conserved across microarray platforms
|BMC Genomics|2006|1.5k
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features
|Proceedings of the National Academy of Sciences|2009|1.4k